Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters

Growth Seen In First Full Quarter With Dual Migraine Indications

Oct 05 2021

• By Mandy Jackson

Listen to this article

The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.

Blue Arrows Rising up in wood blocks — Nurtec ODT revenue grew from $43.8m in Q1 to $93m in Q2 and now $136m in Q3 • Source: Alamy

Biohaven Pharmaceutical Holding Company Ltd.. said on 5 October that its migraine drug Nurtec ODT (rimegepant) generated $136m in third quarter net product revenue, which represents a 46% jump from $96m in the second quarter. The Q3 number, announced a month ahead of Biohaven’s audited quarterly earnings report, indicate that the company’s aggressive sales push is paying off across multiple launch parameters.

New Haven, CT-based Biohaven said its drug – which was approved last year in the US as an acute treatment...

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again
Jun 14 2025
• By Nabil
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
Mar 10 2025
• By Dexter Jie Yan
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch
Mar 10 2025
• By Alexandra Shimmings
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.

More from Scrip

sponsored
Sponsored by :
Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.